Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NYSE | Common Stock
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4.
The company was founded in 2018 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.12 Decreased by -94.17% | -0.12 Increased by +2.92% |
| Nov 4, 24 | -0.15 Decreased by -66.67% | -0.13 Decreased by -15.38% |
| Aug 5, 24 | -0.15 Decreased by -66.67% | -0.06 Decreased by -150.00% |
| May 14, 24 | -0.07 Increased by +30.00% | -0.10 Increased by +30.00% |
| Feb 29, 24 | -0.06 Increased by +40.00% | -0.10 Increased by +40.00% |
| Nov 2, 23 | -0.09 Increased by +25.00% | -0.11 Increased by +18.18% |
| Aug 3, 23 | -0.09 Increased by +43.75% | -0.11 Increased by +18.18% |
| May 4, 23 | -0.10 Increased by 0.00% | -0.10 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 5.71 M Increased by +2.06 K% | -49.45 M Decreased by -258.63% | Decreased by -865.79% Increased by +83.42% |
| Sep 30, 24 | 727.00 K Increased by +N/A% | -41.21 M Decreased by -109.73% | Decreased by -5.67 K% Decreased by N/A% |
| Jun 30, 24 | 1.44 M Increased by +N/A% | -462.49 M Decreased by -2.14 K% | Decreased by -32.23 K% Decreased by N/A% |
| Mar 31, 24 | 264.00 K Increased by +N/A% | -14.79 M Increased by +12.63% | Decreased by -5.60 K% Decreased by N/A% |
| Dec 31, 23 | 264.00 K Increased by +N/A% | -13.79 M Decreased by -85.18% | Decreased by -5.22 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Increased by +100.00% | -19.65 M Increased by +21.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Increased by +100.00% | -20.64 M Increased by +35.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -16.93 M Decreased by -17.63% | Decreased by N/A% Decreased by N/A% |